

G OPEN ACCESS

Citation: Chenoweth L, Stein-Parbury J, Lapkin S, Wang A, Liu Z, Williams A (2019) Effects of person-centered care at the organisational-level for people with dementia. A systematic review. PLoS ONE 14(2): e0212686. https://doi.org/10.1371/ journal.pone.0212686

Editor: Stephen D. Ginsberg, Nathan S Kline Institute, UNITED STATES

Received: December 8, 2018

Accepted: February 8, 2019

Published: February 22, 2019

Copyright: © 2019 Chenoweth et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: The authors received no specific funding for this work.

Competing interests: The authors declare that they have no competing interests.

RESEARCH ARTICLE

Effects of person-centered care at the organisational-level for people with dementia. A systematic review

Lynette Chenoweth^{1*}, Jane Stein-Parbury², Samuel Lapkin³, Alex Wang², Zhixin Liu⁴, Anna Williams⁵

1 Centre for Healthy Brain Ageing (CHeBA), Faculty of Medicine, The University of New South Wales Sydney, New South Wales, Australia, 2 Faculty of Health, University of Technology Sydney, New South Wales, Australia, 3 School of Nursing, Faculty of Science, Medicine and Health, University of Wollongong, South Western Sydney Campus, New South Wales, Australia, 4 Stats Central, The University of New South Wales Sydney, New South Wales, Australia, 5 School of Nursing, Faculty of Medicine, The University of Notre Dame Sydney, New South Wales, Australia

* I.chenoweth@unsw.edu.au

Abstract

The aim of the systematic review was to determine the effectiveness of organizational-level person-centered care for people living with dementia in relation to their quality of life, mood, neuropsychiatric symptoms and function. ALOIS, the Cochrane Dementia and Cognitive Improvement Group Specialised Register databases, were searched up to June 2018 using the terms dementia OR cognitive impairment OR Alzheimer AND non-pharmacological AND personhood OR person-centered care. Reviewed studies included randomized controlled trials (RCTs), cluster-randomized trials (CRTs) and guasi-experimental studies that compared outcomes of person-centered care and usual (non-person-centered) care, for people with a diagnosis of dementia. The search yielded 12 eligible studies with a total of 2599 people living with dementia in long-term care homes, 600 receiving hospital care and 293 living in extra-care community housing. Random-effects models were used to pool adjusted risk ratios and standard mean differences from all studies; the findings were assessed followed the PRISMA guidelines and GRADE criteria. Statistical heterogeneity was assessed using the I² method and Chi² P value; studies with low statistical heterogeneity were analyzed using a random-effects model with restricted maximum likelihood estimation in R. Analyses of pre/post data within 12 months identified: a significant effect for quality of life (standardized mean difference (SMD) 0.16 and 95% CI 0.03 to 0.28; studies = 6; I^2 = 22%); non-significant effects for neuropsychiatric symptoms (SMD 0.06, 95% CI -0.08 to 0.19; studies = 4; $I^2 = 0\%$) and well-being (SMD 0.15, 95% CI -0.15 to 0.45; studies = 4; $I^2 = 0\%$ 77%); and no effects for agitation (SMD -0.05 (95% CI -0.17 to -0.07; studies 5; $I^2 = 0\%$) and depression (SMD -0.06 and 95% CI -0.27 to 0.15, studies = 5; I^2 = 53%). The evidence from this review recommends implementation of person-centered care at the organizational-level to support the quality of life of people with living with dementia.

Introduction

Fifty million people world-wide presently live with dementia [1] and approximately 65.7 million people are projected to be associated with the disorder by 2030 [2]. Encompassing a range of neurocognitive disorders, dementia is distinguished by progressive decline in cognition and impairment in function. Providing care for people with living with dementia is often exhausting and stressful for families and often at a late stage of the disorder, the person will require formal care support, such as long-term residential care [3]. There is growing awareness among healthcare service providers that person-centred care (PCC) is the preferred model of dementia care [1,3,4]. PCC focuses on supporting the person's remaining abilities, rather than on the losses occurring [4,5], and it recognises the importance of knowing the individual's history, personality and preferences, bringing the person into shared decisions on their care [6,7], and customizing care and lifestyle support accordingly [7].

The social-psychological theory of personhood in dementia [7] provides the basis for the PCC approach; it proposes that people exist in a social, relational context, and that positive and enriching interpersonal relationships can prevent the disabling effects of dementia and promote a sense of well-being [7,8,9]. Since the person's life experiences are constructed by the social-psychological milieu, this can often have a more significant effect on the person than the illness itself, by influencing their relationships with caregivers [10]. Kitwood developed a set of guiding PCC principles [7] to help caregivers support the person's well-being, which include: creating and strengthening a positive relationship with the person through warm and accepting human contact; communicating respectfully, valuing and honoring the person; treating the person to retain their remaining strengths; viewing the person's world from their own perspective; and enabling the person to feel socially confident and maintain emotional attachments [7,8,9].

Multiple sources, including international policy [1, 3], dementia advocacy groups [10] and national Dementia Strategies, for example in the UK [11] and Australia [12] advocate PCC for people living with dementia. This recommendation is based on the evidence that PCC can reduce the incidence of clinical issues, such as agitation [13] and delirium [14], and it can help with deprescribing of psychotherapeutic medicines [15]. Despite evidence of the effectiveness of PCC, a pervasive challenge in applying the PCC across healthcare services is the construction of dementia as a master status through use of labelling and social positioning, in which the person's dependency and a lack of autonomy are expected by caregivers. When this attitude prevails in healthcare services, care becomes focused on compensating for the loss of functional and cognitive abilities rather than supporting remaining abilities [16]. This attitude extends to normalizing the presence of agitation and other neuropsychiatric symptoms in dementia, attributing dementia as the cause rather than the care context [11]. These prevailing caregiver attitudes serve to distance the caregiver from the person living with dementia, resulting in their diminished personhood [7, 11]. These non-PCC practices largely occur because caregivers are unclear on how to integrate PCC principles within existing healthcare services that are constrained by established ways of delivering health care (micro and macro levels) and because of task-focused workplace cultures [17, 18].

Redressing these limitations demands reconceptualizing the organization's approach to dementia care, instituting enabling and proactive organizational support, attending to managerial and senior staff leadership, and providing targeted staff education, training, direct supervision and oversight of PCC [19,20,21]. Organizational-level provision of PCC requires a top down, bottom up approach; leadership is required from the top and staff caregivers must be equipped with PCC knowledge, skills and attitudes. While individual caregivers need to be

skilled in the delivery of person-centred care, the entire organisation must also be supportive. Organisational leaders need to demonstrate commitment and support by articulating a clear vision of PCC, allocating sufficient resources that enable PCC implementation, and establishing and exhibiting values of organization-wide respect, empowerment and choice for the person, their family/advocates and their caregivers [4,5,6,20,21,22]. Leaders need to demonstrate attitudes and behaviours that support PCC by placing relationships before tasks in the care planning and delivery and enabling caregivers to balance the values and wishes of the person (and their family/advocates) with organizational values, in order to provide personalized care delivery in daily practice [4,5,6,17,18, 20–23]. In addition, a shared governance system needs to be established such that caregivers become part of the decision-making process by seeking their input and feedback on decisions regarding changes to policies and procedures, redesigning the care environment, and determining the effect of changes on daily workflow [5,6,21,22,23]. Finally, the physical environment needs to be adapted in order to support the person's right to privacy, maximise the person's independence, enable the person to make the best use of their capabilities, provide the person with opportunities to participate in community life and maintain emotional connections, and empower the person to feel psychologically secure, and physically comfortable and safe [4,5,6,23].

In establishing this level of organizational support of PCC, a coordinated approach is needed to communicate the common values of PCC across the healthcare organization. This requires a shift in the organization's strategic direction, whereby the work culture, leadership and support to individuals within the care relationship must align with person centered values [7,8,9, 21,23]. The organization's executive and managers must also create a climate of understanding and acceptance among staff that the change process will take some time and will require a great deal of commitment and effort by all members of the organization [20]. Healthcare providers, managers and direct caregivers will need to be part of the change process by embracing a reconceptualized future for the organization, the care recipients and themselves, and by investing in staff who are future oriented [21,23]. To achieve this, organizational systems must facilitate clear communication on PCC requirements, provide capacity for speedy problem solving among all team members [19, 21, 23], encourage new ideas and incorporate an effective way of discovering what is/not working for the person with dementia and respond accordingly [21,22].

A coordinated and sustained cultural and structural transformation supporting PCC requires the healthcare service to focus on respectful and positive relationships between caregivers, people living with dementia and their families, improved capacity of caregivers to provide PCC through the development of knowledge and skills, supporting the dignity and autonomy of the person living with dementia, and promoting collaboration and team work in delivering care that aims for well-being [18, 22,23]. These requirements are encapsulated in the VIPS framework [24] which provides guidance on organizational-level implementation of PCC, paying attention to the following four key elements:

1. Valuing: valuing service user and service staff.

The organization's mission statement identifies provision of a person-centred service; Human resources management ensure staff feel valued by their employer; Management practices are empowering to direct service staff; Management supports training and development for staff to be skilled in person-centred care; Management provides supportive and inclusive physical and social environments for people with cognitive disability; and Continuous quality improvement mechanisms are in place that are driven by knowing and acting upon the needs and concerns of service users. 2. Individualized Care: Treating people as individuals.

Strengths and vulnerabilities of service users are recognised across a wide range of needs; Care plans are individualized that reflect a wide range of strengths and needs; Individual care plans are reviewed on a regular basis; Service users have their own personal clothing possessions for everyday use; Individual likes and dislikes, preferences and daily routines are known about by direct care staff and are acted upon; Care staff are aware of basic individual life histories and key stories of proud times, and are used regularly; and A variety of activities are available to meet needs and abilities of all service users.

- 3. Personal perspective: looking at world from perspective of person with dementia. Service users are asked for their preferences, consent and opinion on a day-to-day basis; Staff show the ability to put themselves in the position of the person they are caring for and think about decisions from their point of view; The physical environment (e.g. noise, temperature) is managed on a day-to-day basis to help people with dementia feel at ease; Physical health needs of people with dementia, including pain assessment, sight and hearing problems, are given due attention; 'Challenging behaviour' is analysed to discover the underlying reasons; and Rights of individuals are protected in situations where actions of an individual are at odds with the safety and well-being of others.
- Social environment: the total human relationship environment, including staff /service user relationships.

Staff help all service users to be included in conversations and help them to relate to others, despite cognitive and mental ability; Service users are treated with respect, with an absence of people being demeaned by 'telling-off' or labelling; There is an atmosphere of warmth, acceptance and comfort to service users; Service users' fears are taken seriously; Service users are not left alone for long periods in emotional distress; Staff help service users, including those with cognitive disabilities, to be active in their own care and other activities of daily living, and not treat them as objects with no feelings; and Service users are encouraged to use local community facilities and to encourage people from local community to visit regularly.

Two validated assessment tools can be used to assesses aspects of the organizational requirements to support PCC; the Short Observation Framework for Inspection, version 2 (SOFI 2) [25] and the 76-item Person-Centred Environment and Care Assessment Tool (PCECAT) [26]. The SOFI 2 [25] is one component of the Care Quality Commission (CQC) inspection toolkit used to assess the quality of social care services according to the VIPS framework [24], chiefly in the United Kingdom. CQC inspectors use SOFI 2 [25] to observe the mood and engagement of people using services and the quality of staff interactions, and other aspects of care practice during their observations. This assessment tool, therefore, focuses more attention at the individual level of care services. By contrast, the PCECAT [26] assesses both the organisational elements that support PCC for people living in aged care homes, as well as service quality according to PCC principles. It aligns with care home accreditation standards in the Australasian region. The PCECAT [26] includes items on organisational characteristics such as staffing numbers, mix, skills and education in PCC, the organisational culture, care delivery systems, service quality systems, social and therapeutic activity programs, interpersonal relationships and interactions between individuals and caregivers, and the physical layout and design. The PCECAT [26] enables care service providers and assessors to evaluate whether and how PCC is occurring at the individual level and how PCC is being supported at the organizational-level.

Methods

Review objective

With reference to the requirements of the four VIPS [24] elements, the objective of the review was to determine the effectiveness of organization-level PCC interventions for people living with dementia, in relation to: reduction of neuropsychiatric symptoms, including agitation; changes in mood, including depression and well-being; improvement in quality of life; improvement in activities of living; alterations in the use of restraint (physical and/or chemical); and reduction in adverse events, such as falls. The review is registered with PROSPERO, Review Registration Number: PROPSERO 2018 CRD420181C0431.

Review criteria

The review of studies on PCC in healthcare services for people with dementia was undertaken in accordance with the review protocol [27]. We included randomized and cluster-randomized controlled clinical trials, and quasi-experimental studies published in English, which evaluated the effectiveness of providing PCC at the organizational level for people with dementia in formal healthcare services, according to the VIPS requirements [24], compared to care that was routinely undertaken in healthcare services, i.e. non-PCC. Healthcare settings included long-term care homes, hospitals and community-based services. Study participants included people diagnosed with dementia according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) [28] and/or the International Classification of Diseases (ICD) [29].

We excluded studies that were: not specific to dementia; focused on dementia caregiver support and/or burden; and directed at early detection of dementia; and studies which tested targeted interventions for dementia, including psychosocial approaches, that were not identified as PCC.

Search strategy and inclusion/exclusion of studies. Author LC executed the search strategy, assisted by JSP and SL. Bi-monthly searches were conducted in ALOIS [30] the Cochrane Dementia and Cognitive Improvement Group Specialised Register, from 1 June 2016 to 1 June 2018. The search terms included: Dementia, Delirium, Amnestic, Cognitive Disorders, dement*, alzheimer*, organic brain disease or organic brain syndrome; cerebral*; AND, activity, activities, psychosocial, non-pharmacological, individually-tailor*, personally-tailor*, individual or individuals or individually-cent*, meaning* or meaningful*, engagement or engaging, occupational*, personhood, person-centred, patient-centred care; AND; randomized controlled trial, controlled clinical trial, randomly, placebo, randomized, randomised, double-blind* or single-blind* RCT or CRCT. The following databases were accessed: MED-LINE (via the Ovid SP platform), EMBASE, CINAHL, PsycINFO, and LILACS; Trial registers: meta Register of Controlled Trials, Umin Japan Trial Register, WHO Clinical Trials Registry Platform portal, ClinicalTrials.gov, ISRCTN, Chinese Clinical Trial Register, German Clinical Trials Register, Iranian Registry of Clinical Trials, Netherlands National Trials Register, and Central Register of Controlled Trials (CENTRAL) in the Cochrane Library; Grey literature sources: ISI Web of Knowledge Conference Proceedings; Index to Theses, and Australasian Digital Theses; NHS Economic Evaluation Database (NHS EED). In addition, LC, JSP and SL undertook snowballing of the reference list of all studies that were suitable for review. At this stage of the search no restrictions were placed on articles accessed in relation to their methodological quality. The search that was used for the retrieval of reports of trials from MEDLINE (via the Ovid SP platform) can be found in S1 Fig.

The search results for individual databases were combined and duplicate records were removed. LC and JSP independently reviewed the titles and abstracts of each study to

determine their eligibility for inclusion in the review, based on the review aims and criteria for inclusion. LC and JSP discussed any disagreements about study eligibility after reviewing the full published articles which met the review criteria, and referred any that were unresolved to reviewer SL.

Methodologic quality assessment. Reviewers SL and AYW independently assessed the quality of studies using criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions [31] using the GRADE criteria [32]. This set of criteria includes evidence of associations between overestimate of effect and high risk of study bias, such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. On review of the included studies, there was a conflict of interest for two of them which were authored by reviewers LC and JSP [33,34]. Consideration of these two studies for inclusion in the review was determined by an external reviewer (EB), who used the same Cochrane criteria and GRADE to independently review these two studies. Due process was followed in dealing with review author conflict of interest [32].

Data extraction. LC and JSP independently extracted data from each included study using the Template for Intervention Description and Replication (TIDieR) checklist [35]. Information recorded included country of origin, publication date, trial registration number and ethical approval details, number of participants receiving each intervention, gender, age, type of dementia diagnosis, study setting, description of control and PCC intervention components, total duration of the PCC intervention, follow-up period, outcome measurements targeted and results for experimental and control study groups. The Templates were cross-checked by authors LC, JSP, SL and AYW.

The corresponding authors of five included studies [33,34,36,37,38] were contacted by author SL to obtain further information on statistical tests and test results for primary outcomes of interest. Further information was provided on all statistical tests used, as well as raw group means and standard deviations (SD) for four of the studies [33,34,36,38]. For one study [37] where these data were not available, the following procedure was followed: where there were missing measures of variance for continuous data, but an exact standard error (SE) and/ or Confidence Intervals (CI) available for group means, and either P value or t value available for differences in mean, SL, ZL and AYW calculated the SDs using generic inverse variance calculator according to the rules described in the Cochrane Handbook for Systemic reviews of Interventions [31]. These results were included in the data extraction tables.

Review of person-centred care interventions across studies. The TIDieR checklist [35] was used by authors LC and JSP to list the components of the PCC interventions for the 12 studies reviewed. The intervention components were reviewed against the four elements of the VIPS framework [24] and the PCECAT tool [26] for implementation of PCC at the organisational level.

Statistical analysis. Analysis were undertaken by ZL, AYW and SL for all primary and secondary outcome data, measuring standardized mean difference (SMD) on an intention-to-treat basis for all study participants. The denominator for each outcome was the number ran-domized, minus any participants whose outcomes were known to be missing, with the cluster constituting the unit of analysis. The reported methods accounting for cluster randomization in each study were accepted as appropriate, however, if methods were not reported and unavailable, the data were re-analyzed following the Cochrane Handbook guidelines [31].

Statistical heterogeneity was assessed using the I² method and Chi² P value [39]. Heterogeneity was regarded as substantial if an I² was greater than 75% and accompanied by a statistically significant Chi² statistic as evidence. The results were presented as the average treatment effect with 95% confidence intervals, and the estimates of Tau² and I². SL, AYW and ZL undertook additional analysis using a random-effects model with restricted maximum likelihood

estimation, for first/last time point data within 12-months in R [40]. Data were further analyzed applying unit of analysis errors according to Effective Practice and Organisation of Care (EPOC) [41] guidelines and using absolute risk differences [42].

Sensitivity analyses were then conducted for risk of bias [32] by each outcome, in one or more of the domains of randomization (i.e. implied as randomized with no further details available), allocation concealment, blinding and outcome reporting for the meta-analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then data from these trials were included in the analysis [31].

Results


Literature search and study characteristics

The search yielded a total of 8127 study titles and abstracts from ALOIS [30], 1022 remained after the removal of 7105 duplicates and were subjected to title and abstract screening, and 991 of the studies which failed to meet the review inclusion criteria [27] (i.e. experimental studies, focusing on people with dementia, organization-level PCC interventions) were removed. Only 31 of the remaining studies met the review inclusion criteria on reading the study abstracts. Full-text versions of these 31 studies were reviewed against the predefined eligibility criteria [27]. Nineteen of the 31 studies were excluded from full review as four breached the RCT criteria through planned control group exposure to PCC, seven included PCC trial protocols, seven were sub-studies of PCC trials, and one study included some participants without dementia. The full review yielded 12 studies fulfilling all review criteria (N = 3402 study participants) (Fig 1). Of these 12 studies two were conducted in Australia, one in Germany, two in the Netherlands, one in Scandinavia, four in the UK and two in the USA.

A breakdown of the studies eligible for inclusion in the review included 11 cluster-randomized controlled trials (CRCT) [15,33,34,36,38,44–49] and one quasi-experimental study [37]. All 12 studies compared PCC with usual care, i.e. non-PCC, using multi-modal PCC approaches at the organizational level (Table 1). While there were some differences in the way that PCC was implemented, all of the 12 studies adhered to the four VIPS [24] elements and systems requirements as follows:

Across all 12 studies, there was an emphasis on valuing the service user and the service staff. Executive and management staff established systems to support the adoption of PCC among all levels of staff, and they empowered the trained PCC champions/coaches to assist direct service staff in reconceptualizing care and therapy practices. All 12 studies focused on developing direct care staff and care manager knowledge, attitudes and skills through staff training in PCC, complemented by PCC skills modelling and supervision by PCC champions/coaches, and managerial leadership for PCC at a systems-level. One hospital-based study [38] included all members of the healthcare team in learning how to apply PCC in recognizing, preventing and managing delirium and agitation more therapeutically. Additionally, all 12 studies educated, trained and supervised direct care staff to undertake person-centered care planning in consultation with the service user and/or their family members, which formed the basis for providing individualized care. The same processes occurred for planning and delivering social, therapy and activity programs targeted to individual strengths, needs and preferences, in which family members were encouraged to participate. This emphasis on provision of individualized care and therapy programs, aimed to acknowledge and support unique service user strengths and vulnerabilities across a wide range of needs. Person-centered, non-pharmacological approaches to reducing neuropsychiatric symptoms, such as agitation, was a motif of all 12 studies.

PLOS ONE





https://doi.org/10.1371/journal.pone.0212686.g001

This was enabled through targeted staff education and supervision, champion/coach role modelling, casework discussions among the team, and managerial leadership, which aimed to change staff attitudes to ways of caring for people with dementia. In achieving this goal, direct care staff were encouraged to seek out information on the individual life stories, personalities and achievements, and to employ this knowledge in delivering therapeutic care. Staff were also encouraged to draw on this knowledge in developing closer relationships with the service user and their family members, and to facilitate a more engaged social environment. This also occurred through provision of a greater variety of activities available to meet needs and

Table 1. Characteristics of included studies.

Author Year Country	Methods	Study setting	Participant Characteristics	Intervention Characteristics	Primary outcome	Secondary outcomes	Risk of bias ra	ting *
Brooker et al. 2011 UK	Cluster randomised controlled trial, with four	10 extra care housing schemes	293 residents Age: 81.50 ± 8.05 Gender: 221 women, 72 men	Person-centred Enriched Opportunities	Quality of Life (QOL-AD) ¹	Mood—Depression (GDS) ² , Mood- Well- being (DCM-WIB) ³ ,	Selection bias Performance bias	Low High
UK	measurement points: baseline,	schemes	72 men	Programme (EOP) was compared with Care as Usual		Social integration and support (DSSI) ⁴ , Occupation/activity	Detection bias	High
	6, 12 and 18			(control)		engagement (chart	Attrition bias	Low
	months			Duration of EOP 12 months		review), Transfer to hospital/ high level care (chart review)	Reporting bias	Low
Chenoweth	Cluster	15	289 residents Age:	Two PCC	Agitated behaviour	Neuropsychiatric	Selection bias	Low
et al. 2009 Australia	randomised controlled trial, with three	accredited aged care units within	Mean age of participants for each arm: Dementia care	approaches (PCC and DCM) were compared with each	(CMAI) ⁵	symptoms (NPI-NH) ⁶ , Quality of life (QUALID) ⁷ ,	Performance bias	High
Australia	measurement points: baseline,	12 residential	mapping: 83 ± 7.6 Person-centred care:	other and with Care as Usual (control).		Quality of care interactions (QUIS) ⁸ ,	Detection bias	Low
	4 and 8 months	aged care homes	84 ± 6.4 Usual care: 85 ± 6.6	Duration of PCC and DCM		Well-being (DCM-WIB) ³ ,	Attrition bias	Low
Chenoweth	Cluster		Gender: 224 women, 65 men 601 residents	interventions 8 months	Agitated behaviour	Psychotropic drug use (chart review), Adverse events and associated medical consults and hospitalisation (chart review), Care manager support for PCC champions and DCM trained staff (survey), Cost benefit of PCC and DCM implementation (economic analysis) Quality of care	Reporting bias Selection bias	Low
et al. 2014 Australia	randomised controlled trial, with three	38 aged/ dementia care units within 38	Age: Mean age of participants for each arm:	Three person- centred service approaches (PCC, PCE, PCC+PCE)	(CMAI) ⁵ , Quality of life (DEMQOL) ⁹ , Emotional responses in	interactions (QUIS) ⁸ , Mood depression (CSDD) ¹¹ ,	Performance bias	Low
Australia	measurement points: baseline,	residential aged care	Person-centred care: 84 ± 8	were compared with each other and with	care (ERIC) ¹⁰	Psychotropic drug use (chart review),	Detection bias	Low
	4 and 8 months	homes	Person-centred	Care as Usual		Adverse events and	Attrition bias	Low
			environment: 84 ± 8 Person-centred care + person-centred environment: 84 ± 7 Usual care: 86 ± 7 Gender: 481 women, 120 men	(control). Intervention Duration for PCC 8 months, for PCE 6 months and for PCC +PCE 6-8 months		associated medical consults and hospitalisation (chart review), Cost benefit of PCC, PCE and PCC+PCE implementation (economic analysis)	Reporting bias	Low

(Continued)

Table 1. (Continued)

Author Year Country	Methods	Study setting	Participant Characteristics	Intervention Characteristics	Primary outcome	Secondary outcomes	Risk of bias ra	ting *
Cohen- Mansfield et al. 2012	Randomised placebo- controlled	9 nursing homes	125 residents, > = 60 years old Age: Mean age of	Person-centred, non- pharmacological	Agitation (ABMI) ¹² , Pleasure, interest and mood (LMBS) ¹³	Anti-depressant and anti-anxiety medication use (chart	Selection bias Performance bias	Low High
USA	clinical trial, with two measurement		residents at baseline: All residents: 85.7 ± 8.89	management of agitation TREA (Treatment Routes		review)	Detection bias	Low
	points: baseline,		Intervention group:	for Exploring			Attrition bias	Low
	2 and 3 weeks		85.9 ± 8.62 Control group: 85.3 ± 9.62 Gender: 93 women, 32 men	Agitation) was compared to Care as Usual plus in-service staff education (control). Duration of TREA 2 weeks			Reporting bias	Low
Dichter et	Pragmatic	9 nursing	Age:	Person-centred	Quality of Life	Neuropsychiatric	Selection bias	High
al. 2015 Germany	quasi- experimental trial, with three	homes	Dementia care mapping with prior	intervention DCM was compared for staff with prior	(QOL-AD ¹ proxy) and (QUALIDEM) ⁷	symptoms (NPI-NH) ⁶	Performance bias	High
	measurement points: baseline,		experience group: 82 ± 6.8 Dementia care	DCM experience and staff with no			Detection bias	High
	6 and 18		mapping with no	prior DCM			Attrition bias	Low
	months		prior experience group: 84.1 ± 6.3 Usual care group: 82.6 ± 9.2 Gender: 128 women, 26 men at baseline 40 new residents were recruited during the course of the study	experience and with Care as Usual (control) Duration of DCM 12–18 months			Reporting bias	Low
Finnema et al. 2005 Netherlands	Cluster randomised control trial,	16 nursing home units	194 residents Age: Mean age of residents at baseline:	Person-centred care using emotion- oriented approaches	Adaptation-coping (BOP [Beoordelingsschaal	Mood-Depression (CSDD) ¹¹ Morale (PGCMS) ¹⁵ Agitation	Selection bias Performance bias	Low High
	with three measurement points: baseline,		Intervention group: 83.8 ± 5.3 Control group:	was compared with Care as Usual (control)	voor Oudere Patie ["] nten]) ¹⁴	(CMAI) ⁵ , Staff Self-rated Health (GHQ-28) ¹⁶ , Staff	Detection bias	Unclear
	3 and 7 months		83.6 ± 5.8	Intervention Dose		work satisfaction and	Attrition bias	Low
			Gender: Not reported	100% Intervention Duration of PCC 7 months		sense of competence (Dutch Work Satisfaction Scale) ¹⁷	Reporting bias	Low
Fossey et al.	Cluster	12 specialist	349 residents Age:	Person-centred non-	1	Agitation (CMAI) ⁵ ,	Selection bias	Low
2006 U.K.	randomised controlled trial, with three	nursing homes for	Median age and range of residents at baseline:	pharmacological management of	prescribing/use and dose (chart review)	Mood- Well-being (DCM-WIB) ³ , Incidents of irritable	Performance bias	Unclear
	measurement points: baseline,	people with dementia	Intervention group: 82 (60–98)	neuropsychiatric symptoms was compared to Care as	Other psychotropic drug prescribing and use (chart review)	and aggressive behaviour (chart	Detection bias	Unclear
	3 and 12		Control group: 82	Usual (control).		review) Adverse	Attrition bias	Low
	months		(53–101) Gender: 130 women, 219 men	Duration of PCC 10 months		events (incl. falls) (chart review)	Reporting bias	Low

(Continued)

Table 1. (Continued)

Author Year Country	Methods	Study setting	Participant Characteristics	Intervention Characteristics	Primary outcome	Secondary outcomes	Risk of bias ra	ting *
Goldberg	Cluster	Acute	600 patients aged	Person-centred	Number of days spent	Mood-well-being	Selection bias	Low
et al. 2013 U.K.	randomised controlled trial, with three	general hospital	over 65 admitted for acute medical care	approach to delirium prevention	at home after hospitalisation,	(DCM-WIB) ³ , Quality of life (DEMQOL proxy) ⁹	Performance bias	High
	measurement points: baseline,		Age: Median age and range of residents at baseline:	and management in people with dementia were	Number of days spent in hospital, Mortality rate, Re-	and EuroQolEQ- 5D) ¹⁸ Disability	Detection bias	Low
	at discharge and		Intervention group:	compared to Care as	admission to hospital,	(Short London	Attrition bias	Low
	3 months		85 (80–88) Control/standard care group: 85 (80– 89) Gender: 312 women, 288 men	Usual services (control). Duration of PCC 90 days (median 11 days/ patient)	In-patient rehabilitation or intermediate care New placements in a care home (chart and hospital record reviews)	Handicap Scale) ¹⁹ , function (Barthel Index) ²⁰ , Neuropsychiatric symptoms (NPI) ²¹ , Carer strain (CSI) ²² , Carer self-reported health (GHQ-12) ²³ , Carer satisfaction	Reporting bias	Low
Lawton et	Cluster	Two	182 residents	Person-centred care	Affective state/Pleasure	Aggression/	Selection bias	High
al. 1998 USA	randomised control trial, with three	equivalent/ matched	Age: not reported Gender: not	using the Stimulation-Retreat	(MOSES) ²⁴ and (AARS) ²⁵ , Mood- Depression (MDS) ²⁶ ,	irritability (BEHAVE-AD) ²⁷ ,	Performance bias	High
USA	measurement points: baseline,	special care nursing home units	reported	model, compared to Care as Usual (control). Duration	Social Quality, Time Use, Sociability	Agitation $(CMAI)^5$ and $(BRS)^{28}$, Repetitive behaviour	Detection bias	High
	6 and 12			of PCC 12 months	(MDS) ²⁶ and	(MDS) ²⁶ , Functional	Attrition bias	Low
	months				(MOSES) ²⁴ , Gazing with Interest, Length of emotion display in activities (AARS) ²⁶ and (MOSES) ²⁵	health (PSMS) ²⁹ , Cognition (GDS) ²	Reporting bias	Low
Li et al. 2015	Cluster	Two secure	26 residents \geq 65	Person-centred care,	Total hours and % of	Social and physical	Selection bias	High
USA	randomised controlled trial, nested within a	dementia care units	years old Age: Mean age for all	compared with Care as Usual (control). Duration of PCC 4	sleep in 24 hours (Actiwatch) ³⁰ Number of awakenings from	engagement (DCM-WIB) ³	Performance bias	High
	larger study, with two		residents: 86.45 ± 6.90	weeks	sleep in 24 Hrs (Actiwatch) ³⁰ Daytime		Detection bias	High
	measurement		Intervention group:		physical and social		Attrition bias	Low
	points: baseline and 1 month		$\begin{array}{l} 85.67 \pm 5.16 \\ \text{Control group:} \\ 88.66 \pm 5.16 \\ \text{Gender:} \\ \text{Not reported at} \\ \text{baseline} \end{array}$		activity (Actiwatch) ³⁰ Daylight exposure (Light sensor)		Reporting bias	Low
Rokstad	Cluster-	15 nursing	624 residents	Two person-centred	Agitation (BARS) ³¹	Neuropsychiatric	Selection bias	Low
et al. 2013 Norway	randomized controlled trial with two	homes with a total of 40 units	Age: Mean age for all residents:85.7 ± 8.3	care approaches (DCM and VPM) were compared with		symptoms (NPI) ²¹ , Mood Depression (CSDD) ¹¹ , Quality of	Performance bias	High
1101 way	measurement points: baseline		Dementia care mapping group:	each other and with Care as Usual		life (QUALID) ⁷ Activities of daily	Detection bias	Low
	and 10 months		85.1 ± 8.7	(control)		living (PSMS) ²⁹	Attrition bias	Low
			VIPS practice model group: 85.1 ± 8.7 Control group: 87.0 ± 8.3 Gender: 448 women, $176men$	Duration of DCM and VPM 10 months		General health (GMHRS- modified) ³²	Reporting bias	Low

(Continued)

Table 1. (Continued)

Author Year Country	Methods	Study setting	Participant Characteristics	Intervention Characteristics	Primary outcome	Secondary outcomes	Risk of bias ra	ting *
Van de Ven	Cluster	11 nursing	192 residents with	The DCM approach	Primary outcome:	Neuropsychiatric	Selection bias	Low
et al. 2013	randomised controlled trial,	care homes and 34 units	dementia Age: Mean age of	to Person-Centred Care was compared	Agitation (CMAI) ⁵	symptoms (NPI-NH) ⁶ , Quality	Performance bias	High
Netherlands	with three measurement points: baseline,		residents at baseline: Intervention group: 84.6 ± 6.1	with Care as Usual (control) Duration of DCM 8		of life (Qualidem) ³³ and (EuroQol 5D) ¹⁸ , Staff health and stress	Detection bias	Low
	4 and 8 months		Control group:	months		(GHQ-12) ²³ , Staff Job	Attrition bias	Low
			83.5 ± 6.6 Gender: 143 women 49 men			satisfaction (MJSS-HC) ³⁴	Reporting bias	Low

*Risk of bias rating adopted from the Cochrane Collaboration's tool for assessing risk of bias

References for study measures 1-34 can be found in S1 Table.

https://doi.org/10.1371/journal.pone.0212686.t001

abilities of service users. Four studies [15,34,38,49] adapted the care environment using person-centered environmental principles, making it less restrictive, more comfortable, recognizable, interesting and interactive, and helping to orient the service user to the current situation while supporting their capabilities.

Comparison groups in all 12 studies provided usual (non-person-centered) care, social and recreation activity programs in other care units, wards or services without any planned exposure to person-centered models and systems. Follow-up assessment ranged from 3 weeks to 3 months [36,44,45], 4 to 8 months [33,34,38,48] and 10 to 18 months [15,37,46, 47,49].

The mean participant ages were 81–86.45 years and 65% were female, and all participants had a diagnosis of dementia and presence of neuropsychiatric symptoms that caregivers found troublesome. Participant attrition ranged from 20–30% in the 10 studies undertaken in long-term care homes. Most of the participants had more than one comorbidity and all had some functional impairment associated with older age and/or dementia.

Table 1 summarizes the participant, site and study characteristics, study intervention and measurement, and the risk of bias ratings of all 12 studies.

Primary participant outcomes

The results of analyses of pooled data for the primary participant outcomes from studies measuring these outcomes are presented in Fig 2, followed by results of the sensitivity analysis in studies with low statistical heterogeneity in Fig 3.

Neuropsychiatric symptoms. Six studies [33, 37,38,46,47,48] reported a non-significant reduction in the standardized mean score of neuropsychiatric symptoms with person-centered care compared with usual care (SMD 0.13, 95% CI -0.21 to 0.49; studies = 6; I^2 = 88%) (Fig 2). Sensitivity analysis was not conducted since only two of the studies had low risk of bias [33,47] (Table 1). In four of the studies with low heterogeneity [37,38,47,48] there was a non-significant reduction in neuropsychiatric symptoms (SMD 0.06, 95% CI -0.08 to 0.19; studies = 4; participants = 895; I^2 = 0%) as shown in Fig 3.

Agitation. Eight studies [15,33,34,36,44,46,47,48] produced a non-significant reduction in agitation (SMD -0.54, 95% CI -1.23 to 0.15; studies = 8; $I^2 = 97\%$). Sensitivity analysis of five studies with low risk of bias [15,33,34,36,47] showed an increased overall effect for the person-centered care group (p < 0.00001, SMD 0.38, 95% CI -0.50 to -0.25). Analysis of five studies with low heterogeneity [15,34,46,47,48], however, showed no significant difference in agitation

	c Symp								
04 June 0 1		PCC	T -4 •		Control	T-4 -		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean		Total				Weight	IV, Random, 95% CI	IV, Random, 95% CI
Chenoweth 2009	12.6	6.9	77	15.3	5.3	64	16.1%	-0.43 [-0.77, -0.10]	
Dichter 2015	16.95				32.0029	59	15.6%	0.12 [-0.25, 0.48]	T
Goldberg 2013	22.5	20.6	154	22.2	21.5	142	18.1%	0.01 [-0.21, 0.24]	†
Lawton 1998	2.16	1.91	59	0.68	1.05	59	15.3%	0.95 [0.57, 1.34]	
Rokstad 2013	5.3	5.5	158	5.5	4.5	150	18.1%	-0.04 [-0.26, 0.18]	Ť
van de Ven 2013	6.28	7.9141	74	4.13	8.6856	102	16.8%	0.26 [-0.04, 0.56]	† = -
Total (95% CI)			578			576	100.0%	0.13 [-0.17, 0.44]	•
Heterogeneity: Tau ² =	0.12: Chi	i ^z = 31.86	df = 5	(P < 0.0	0001); I ? =	84%			
Test for overall effect					/1 ·				-4 -2 0 2 4 Favours [PCC] Favours [Control]
Agitation									
		PCC	_		Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mear			al Mea			I Weight		IV, Random, 95% Cl
Chenoweth 2009	37.2								
Chenoweth 2014	48								-+
Cohen-Mansfield 201									-
Fossey 2006	41.6								1
Lawton 1998	32.66								-+
Rokstad 2013	17.2		9 15						1
van de Ven 2013	48.18	3 19.785	3 7	4 45.8	19.896	6 102	2 14.5%	0.12 [-0.18, 0.42]	+
Total (95% CI)			68	3		626	5 100.0%	-0.54 [-1.07, -0.00]	•
Heterogeneity: Tau ² =	0.49; Chi ^z	= 126.22	df= 6	(P < 0.0	0001); I ^z =	95%			
Test for overall effect:									-4 -2 0 2 4 Favours [PCC] Favours [Control]
Depression									
Depression		Dee			0			044 Marca D'77	
Study or Subgroup	Mea	PCC n SE) Tota	I Mear	Control SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI	Std. Mean Difference IV, Random, 95% Cl
Brooker 2011 Chonoweth 2014	-1.					114	20.3%	-0.21 [-0.47, 0.05]	1
Chenoweth 2014		4 7.4061			8.5671	64	16.4%	-0.05 [-0.39, 0.30]	
Cohen-Mansfield 201						36	14.7%	-0.35 [-0.74, 0.04]	
Finnema 2005	8.2					40	12.3%	0.04 [-0.42, 0.50]	
Lawton 1998	0.5					48	14.3%	0.39 [-0.01, 0.79]	
Rokstad 2013	8.	5 5.6) 158	8 7.4	5.7	150	22.1%	0.19 [-0.03, 0.42]	Ē
Total (95% CI)			506				100.0%	0.00 [-0.21, 0.21]	• • • •
Heterogeneity: Tau ² = Test for overall effect:			df = 5 (P = 0.03	3); I² = 59%	6			-4 -2 0 2 4 Favours [PCC] Favours [Control]
	Z= 0.01 (
	2= 0.01 (
Well-being	2=0.01 (PCC			Control			Std. Mean Difference	Std. Mean Difference
	2 = 0.01 (Mean	SD	Total		SD	Total	Weight	IV, Random, 95% Cl	Std. Mean Difference IV, Random, 95% Cl
Well-being			113	Mean 1.36		Total	Weight 20.7%	IV, Random, 95% Cl -0.02 [-0.28, 0.24]	
Vell-being Study or Subgroup Brooker 2011	Mean	SD		Mean	SD		Weight	IV, Random, 95% Cl	
Vell-being Study or Subgroup Brooker 2011 Chenoweth 2009	<u>Mean</u> 1.35 0.74	SD 0.5714	113	Mean 1.36	SD 0.5714	114	Weight 20.7%	IV, Random, 95% Cl -0.02 [-0.28, 0.24]	
Vell-being Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014	<u>Mean</u> 1.35 0.74	<mark>SD</mark> 0.5714 0.74	113 77	Mean 1.36 0.68	SD 0.5714 0.72	114 64	Weight 20.7% 20.2%	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41]	
Vell-being Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006	Mean 1.35 0.74 24	SD 0.5714 0.74 24.0199	113 77 64	Mean 1.36 0.68 25	SD 0.5714 0.72 28.0233	114 64 64	Weight 20.7% 20.2% 20.1%	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31]	
Vell-being <u>Study or Subgroup</u> Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013	Mean 1.35 0.74 24 1.1	SD 0.5714 0.74 24.0199 0.4	113 77 64 149	Mean 1.36 0.68 25 0.9	SD 0.5714 0.72 28.0233 0.35	114 64 64 153 44	Weight 20.7% 20.2% 20.1% 20.8%	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76]	
Vell-being <u>Study or Subgroup</u> Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006	Mean 1.35 0.74 24 1.1 1.5	SD 0.5714 0.74 24.0199 0.4 0.4	113 77 64 149 46 449	Mean 1.36 0.68 25 0.9 0.1	SD 0.5714 0.72 28.0233 0.35 0.6	114 64 153 44 439	Weight 20.7% 20.2% 20.1% 20.8% 18.2%	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32]	
Well-being <u>Study or Subgroup</u> Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI)	Mean 1.35 0.74 24 1.1 1.5 : 0.50; Chi	SD 0.5714 0.74 24.0199 0.4 0.4 i ² = 82.03	113 77 64 149 46 449	Mean 1.36 0.68 25 0.9 0.1	SD 0.5714 0.72 28.0233 0.35 0.6	114 64 153 44 439	Weight 20.7% 20.2% 20.1% 20.8% 18.2%	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32]	IV, Random, 95% Cl
Well-being <u>Study or Subgroup</u> Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect	Mean 1.35 0.74 24 1.1 1.5 : 0.50; Chi	SD 0.5714 0.74 24.0199 0.4 0.4 i ² = 82.03	113 77 64 149 46 449	Mean 1.36 0.68 25 0.9 0.1	SD 0.5714 0.72 28.0233 0.35 0.6	114 64 153 44 439	Weight 20.7% 20.2% 20.1% 20.8% 18.2%	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32]	
Vell-being <u>Study or Subgroup</u> Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect	Mean 1.35 0.74 24 1.1 1.5 : 0.50; Chi	SD 0.5714 0.74 24.0199 0.4 0.4 i ² = 82.03 (P = 0.06)	113 77 64 149 46 449	Mean 1.36 0.68 25 0.9 0.1	<u>SD</u> 0.5714 0.72 28.0233 0.35 0.6 00001); I² =	114 64 153 44 439	Weight 20.7% 20.2% 20.1% 20.8% 18.2%	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.61 [-0.03, 1.26]	IV, Random, 95% Cl
Vell-being <u>Study or Subgroup</u> Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Quality of Life	Mean 1.35 0.74 24 1.1 1.5 0.50; Chil Z = 1.87 (SD 0.5714 0.74 24.0199 0.4 0.4 0.4 1 ² = 82.03 (P = 0.06) PCC	113 77 64 149 46 449 df = 4	<u>Mean</u> 1.36 0.68 25 0.9 0.1 (P < 0.0	<u>SD</u> 0.5714 0.72 28.0233 0.35 0.6 0001); I [≠] = Control	114 64 153 44 439 95%	Weight 20.7% 20.2% 20.1% 20.8% 18.2% 100.0%	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.61 [-0.03, 1.26] Std. Mean Difference	IV, Random, 95% CI
Vell-being <u>Study or Subgroup</u> Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Quality of Life <u>Study or Subgroup</u>	Mean 1.35 0.74 24 1.1 1.5 0.50; Chi Z = 1.87 (Mean	SD 0.5714 0.74 24.0199 0.4 0.4 0.4 i ² = 82.03 (P = 0.06) PCC SD	113 77 64 149 46 449 df = 4	Mean 1.36 0.68 25 0.9 0.1 (P < 0.0 Mean	<u>SD</u> 0.5714 0.72 28.0233 0.35 0.6 0001); I [≠] = Control <u>SD</u>	114 64 153 44 439 95%	Weight 20.7% 20.2% 20.1% 20.8% 18.2% 100.0% Weight	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.61 [-0.03, 1.26] Std. Mean Difference IV, Random, 95% Cl	IV, Random, 95% Cl
Vell-being <u>Study or Subgroup</u> Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Quality of Life <u>Study or Subgroup</u> Brooker 2011	Mean 1.35 0.74 24 1.1 1.5 0.50; Chi Z = 1.87 (Mean 2.5	<u>SD</u> 0.5714 0.74 24.0199 0.4 0.4 0.4 i ² = 82.03 (P = 0.06) PCC <u>SD</u> 5.6125	113 77 64 149 46 449 df = 4 Total 126	Mean 1.36 0.68 25 0.9 0.1 (P < 0.0 Mean 0.5	<u>SD</u> 0.5714 0.72 28.0233 0.35 0.6 00001); I [≠] = <u>Control</u> <u>SD</u> 5.7228	114 64 153 44 439 95% <u>Total</u> 131	Weight 20.7% 20.2% 20.1% 20.8% 18.2% 100.0% Weight 16.7%	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.61 [-0.03, 1.26] Std. Mean Difference IV, Random, 95% Cl 0.35 [0.11, 0.60]	IV, Random, 95% Cl
Vell-being <u>Study or Subgroup</u> Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Quality of Life <u>Study or Subgroup</u> Brooker 2011 Chenoweth 2009	Mean 1.35 0.74 24 1.1 1.5 • 0.50; Chi Z = 1.87 (Mean 2.5 -20.8	SD 0.5714 0.74 24.0199 0.4 0.4 0.4 P= 82.03 (P = 0.06) PCC SD 5.6125 19.3049	113 77 64 149 46 449 df = 4 Total 126 77	Mean 1.36 0.68 25 0.9 0.1 (P < 0.0 Mean 0.5 -24.4	<u>SD</u> 0.5714 0.72 28.0233 0.35 0.6 00001); I [≠] = Control <u>SD</u> 5.7228 13.6	114 64 153 44 439 95% Total 131 64	Weight 20.7% 20.2% 20.1% 20.8% 18.2% 100.0% Weight 16.7% 12.1%	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.61 [-0.03, 1.26] Std. Mean Difference IV, Random, 95% Cl 0.35 [0.11, 0.60] 0.21 [-0.12, 0.54]	IV, Random, 95% Cl
Vell-being Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Quality of Life Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014	Mean 1.35 0.74 24 1.1 1.5 = 0.50; Chi Z = 1.87 (Mean 2.5 -20.8 106	SD 0.5714 0.74 24.0199 0.4 0.5714 0.74 24.0199 0.4 0.5 0.5 0.6105 0.6125 19.3049 12.01	113 77 64 149 46 449 df = 4 Total 126 77 64	<u>Mean</u> 1.36 0.68 25 0.9 0.1 (P < 0.0 <u>Mean</u> 0.5 -24.4 103	<u>SD</u> 0.5714 0.72 28.0233 0.35 0.6 00001); I [≠] = <u>Control</u> <u>SD</u> 5.7228 13.6 16.0133	114 64 153 44 •95% •95% • Total 131 64 64	Weight 20.7% 20.2% 20.1% 20.8% 18.2% 100.0% Weight 16.7% 12.1% 11.5%	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.61 [-0.03, 1.26] Std. Mean Difference IV, Random, 95% Cl 0.35 [0.11, 0.60] 0.21 [-0.12, 0.54] 0.21 [-0.14, 0.56]	IV, Random, 95% CI
Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Quality of Life Study or Subgroup Brooker 2011 Chenoweth 2029	Mean 1.35 0.74 24 1.1 1.5 = 0.50; Chi Z = 1.87 (Mean 2.5 -20.8 106	SD 0.5714 0.74 24.0199 0.4 0.4 0.4 P= 82.03 (P = 0.06) PCC SD 5.6125 19.3049	113 77 64 149 46 449 df = 4 Total 126 77	<u>Mean</u> 1.36 0.68 25 0.9 0.1 (P < 0.0 <u>Mean</u> 0.5 -24.4 103	<u>SD</u> 0.5714 0.72 28.0233 0.35 0.6 00001); I [≠] = Control <u>SD</u> 5.7228 13.6	114 64 153 44 439 95% Total 131 64	Weight 20.7% 20.2% 20.1% 20.8% 18.2% 100.0% Weight 16.7% 12.1% 11.5%	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.61 [-0.03, 1.26] Std. Mean Difference IV, Random, 95% Cl 0.35 [0.11, 0.60] 0.21 [-0.12, 0.54]	IV, Random, 95% CI
Vell-being Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Quality of Life Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014	Mean 1.35 0.74 24 1.1 1.5 = 0.50; Chi Z = 1.87 (Mean 2.5 -20.8 106	SD 0.5714 0.74 24.0199 0.4 0.5714 0.74 24.0199 0.4 0.5 0.5 0.6105 0.6125 19.3049 12.01	113 77 64 149 46 449 df = 4 Total 126 77 64	<u>Mean</u> 1.36 0.68 25 0.9 0.1 (P < 0.0 <u>Mean</u> 0.5 -24.4 103	<u>SD</u> 0.5714 0.72 28.0233 0.35 0.6 00001); I [≠] = <u>Control</u> <u>SD</u> 5.7228 13.6 16.0133	114 64 153 44 •95% •95% • Total 131 64 64	Weight 20.7% 20.2% 20.1% 20.8% 18.2% 100.0% Weight 16.7% 12.1% 11.5% 10.1%	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.61 [-0.03, 1.26] Std. Mean Difference IV, Random, 95% Cl 0.35 [0.11, 0.60] 0.21 [-0.12, 0.54] 0.21 [-0.14, 0.56]	IV, Random, 95% CI
Vell-being Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Quality of Life Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Dichter 2015	Mean 1.35 0.74 24 1.1 1.5 0.50; Chi Z = 1.87 (Mean 2.5 -20.8 106 29.23	SD 0.5714 0.74 24.0199 0.4 0.7 0.8 (P = 0.06) PCC 5.6125 19.3049 12.01 10.913	113 77 64 149 46 449 df = 4 Total 126 77 64 52	<u>Mean</u> 1.36 0.68 25 0.9 0.1 (P < 0.0 <u>Mean</u> 0.5 -24.4 103 32.58	SD 0.5714 0.72 28.0233 0.35 0.6 00001); ⁼ = Control SD 5.7228 13.6 16.0133 11.1017	114 64 153 44 95% Total 131 64 53	Weight 20.7% 20.2% 20.1% 20.8% 18.2% 100.0% Weight 16.7% 12.1% 10.1% 17.7%	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.61 [-0.03, 1.26] Std. Mean Difference IV, Random, 95% Cl 0.35 [0.11, 0.60] 0.21 [-0.12, 0.54] 0.21 [-0.14, 0.56] -0.30 [-0.69, 0.08]	IV, Random, 95% CI
Well-being Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Quality of Life Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Dichter 2015 Goldberg 2013	Mean 1.35 0.74 24 1.1 1.5 0.50; Chil Z = 1.87 (Mean 2.5 -20.8 106 29.23 91	SD 0.5714 0.74 24.0199 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4	113 77 64 149 46 449 (df = 4 Total 126 77 64 52 150 158	Mean 1.36 0.68 25 0.9 0.1 (P < 0.0 Mean 0.5 -24.4 103 32.58 92 -22.8	SD 0.5714 0.72 28.0233 0.35 0.6 00001); *= Control 5.7228 13.6 14.0133 11.1017 15	114 64 153 44 95% Total 131 64 53 138	Weight 20.7% 20.2% 20.1% 20.8% 18.2% 100.0% Weight 16.7% 12.1% 11.5% 10.1% 17.7% 18.2%	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.61 [-0.03, 1.26] Std. Mean Difference IV, Random, 95% Cl 0.35 [0.11, 0.60] 0.21 [-0.14, 0.56] 0.21 [-0.14, 0.56] -0.30 [-0.69, 0.08] -0.06 [-0.30, 0.17]	IV, Random, 95% Cl
Well-being Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Quality of Life Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Dichter 2015 Goldberg 2013 Rokstad 2013 van de Ven 2013	Mean 1.35 0.74 24 : 1.1 1.5 ○.50; Chi Z = 1.87 (Mean 2.5 -20.8 106 29.23 91 -21.4	SD 0.5714 0.74 24.0199 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4	113 77 64 149 46 449 df = 4 126 77 64 52 150 158 74	Mean 1.36 0.68 25 0.9 0.1 (P < 0.0 Mean 0.5 -24.4 103 32.58 92 -22.8	<u>SD</u> 0.5714 0.72 28.0233 0.35 0.6 0001); ²= Control <u>SD</u> 5.7228 13.6 16.0133 11.1017 15 7.4	114 64 153 44 439 95% 131 64 53 138 150 102	Weight 20.7% 20.2% 20.8% 18.2% 100.0% Weight 16.7% 12.1% 11.5% 10.1% 17.7% 18.2% 13.7%	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.61 [-0.03, 1.26] Std. Mean Difference IV, Random, 95% Cl 0.35 [0.11, 0.60] 0.21 [-0.14, 0.56] -0.30 [-0.39, 0.017] 0.19 [-0.30, 0.42] 0.09 [-0.21, 0.39]	IV, Random, 95% Cl
Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Quality of Life Brooker 2011 Chenoweth 2019 Brooker 2011 Chenoweth 2019 Chenoweth 2014 Dichter 2015 Goldberg 2013 Rokstad 2013 van de Ven 2013 Total (95% CI)	Mean 1.35 0.74 24 1.1 1.5 0.50; Chi Z = 1.87 (Mean 2.5 -20.8 106 29.23 91 -21.4 -62.45	SD 0.5714 0.74 24.0199 0.4 0.4 (P = 0.06) PCC SD 5.6125 19.3049 12.01 10.9913 16 7.2 18.8391	113 77 64 149 46 449 df = 4 449 df = 4 126 77 64 52 150 158 74 74 701	Mean 1.36 0.68 25 0.9 0.1 (P ≤ 0.0 Mean 0.5 -24.4 103 32.58 92 -22.8 -64.11	SD 0.5714 0.72 28.0233 0.35 0.6 00001); *= Control 5.7228 13.6 16.0133 11.1017 15 7.4 18.9871	114 64 153 44 439 95% 131 64 53 138 150 102 702	Weight 20.7% 20.2% 20.1% 20.8% 18.2% 100.0% Weight 16.7% 12.1% 11.5% 10.1% 17.7% 18.2%	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.61 [-0.03, 1.26] Std. Mean Difference IV, Random, 95% Cl 0.35 [0.11, 0.60] 0.21 [-0.12, 0.54] 0.21 [-0.12, 0.54] 0.30 [-0.69, 0.08] -0.06 [-0.30, 0.17] 0.19 [-0.03, 0.42]	IV, Random, 95% CI
Vell-being Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Quality of Life Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Dichter 2015 Goldberg 2013 Rokstad 2013 van de Ven 2013	Mean 1.35 0.74 24 : 1.1 1.5 : 0.50; Chi Z = 1.87 (Mean 2.5 -20.8 106 29.23 91 -21.4 -62.45 : 0.02; Chi	SD 0.5714 0.74 24.0199 0.4 0.7 28.03 P= 82.03 P= 0.06) PCC 5.6125 19.3049 12.01 10.9913 16 7.2 18.8391 2= 11.42,	113 77 64 149 46 449 df = 4 449 df = 4 126 77 64 52 150 158 74 74 701	Mean 1.36 0.68 25 0.9 0.1 (P ≤ 0.0 Mean 0.5 -24.4 103 32.58 92 -22.8 -64.11	SD 0.5714 0.72 28.0233 0.35 0.6 00001); *= Control 5.7228 13.6 16.0133 11.1017 15 7.4 18.9871	114 64 153 44 439 95% 131 64 64 53 138 150 102 702	Weight 20.7% 20.2% 20.8% 18.2% 100.0% Weight 16.7% 12.1% 11.5% 10.1% 17.7% 18.2% 13.7%	IV, Random, 95% Cl -0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.61 [-0.03, 1.26] Std. Mean Difference IV, Random, 95% Cl 0.35 [0.11, 0.60] 0.21 [-0.14, 0.56] -0.30 [-0.39, 0.017] 0.19 [-0.30, 0.42] 0.09 [-0.21, 0.39]	IV, Random, 95% Cl

Fig 2. Forest plots of primary outcomes from all studies.

https://doi.org/10.1371/journal.pone.0212686.g002

Study or Subgroup		PCC		6	ontrol		•	Std. Mean Difference	Std. Mean Difference
· · · · · · · · · · · · · · · · · · ·	Mean		Total			Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Chenoweth 2009	12.6	6.9	77	15.3	5.3	64	0.0%	-0.43 [-0.77, -0.10]	
Dichter 2015	16.95				32.0029	59	12.9%	0.12 [-0.25, 0.48]	+-
Goldberg 2013	22.5	20.6	154	22.2	21.5	142	33.3%	0.01 [-0.21, 0.24]	+
Lawton 1998	2.16	1.91	59	0.68	1.05	59	0.0%	0.95 [0.57, 1.34]	
Rokstad 2013	5.3	5.5	158	5.5	4.5	150	34.6%	-0.04 [-0.26, 0.18]	+
van de Ven 2013	6.28	7.9141	74	4.13	8.6856	102	19.2%	0.26 [-0.04, 0.56]	† - -
Total (95% CI)			442			453	100.0%	0.06 [-0.08, 0.19]	4
Heterogeneity: Tau ² = Test for overall effect:				= 0.45)	; I² = 0%	J	.00.070		-4 -2 0 2 4 Favours [PCC] Favours [Control]
Agitation		PCC			Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mear		D Tota	al Mear) Tota	Weight		IV, Random, 95% Cl
Chenoweth 2009	37.3	2 9.1	1 77	7 57.7	7 6.1	3 64			
Chenoweth 2014	41								
Cohen-Mansfield 201	2 2.0	8 2.6	8 89	9 7.92	2 9.0	9 36	6 0.0%		
Fossey 2006	41.0	6 7.:	2 172	2 42			2 32.2%	-0.06 [-0.28, 0.15]	+
Lawton 1998	32.6								
Rokstad 2013	17.3		9 158			3 150			1
van de Ven 2013	48.1	8 19.785	3 74	4 45.81	19.89	6 102	2 16.5%	0.12 [-0.18, 0.42]	+
Total (95% CI)			517	7		526	5 100.0%	-0.05 [-0.17, 0.07]	•
Heterogeneity: Tau ² =	0.00: Chi ^a	² = 1.70. d ^a			I² = 0%				<u> </u>
Test for overall effect:			e v	-71	•				-4 -2 0 2 4 Favours [PCC] Favours [Control]
Depression									
		PCC			Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mea			I Mear		Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Brooker 2011	-1				3 4.2708	114		-0.21 [-0.47, 0.05]	
Chenoweth 2014		.4 7.4061			8.5671	64	18.8%	-0.05 [-0.39, 0.30]	-
Cohen-Mansfield 201						36	16.5%	-0.35 [-0.74, 0.04]	
Finnema 2005	8.2					40	13.4%	0.04 [-0.42, 0.50]	+
Lawton 1998	0.5					48	0.0%	0.39 [-0.01, 0.79]	
Rokstad 2013	8	.5 5.6	6 158	8 7.4	4 5.7	150	27.0%	0.19 [-0.03, 0.42]	-
Total (95% CI)			457	7		404	100.0%	-0.06 [-0.27, 0.15]	•
Heterogeneity: Tau ² =	= 0.03; Ch	i ^z = 8.43. (); I ² = 53%			,	<u> </u>
Test for overall effect:									-4 -2 0 2 4 Favours [PCC] Favours [Control]
Well-being		PCC			Control			Std. Mean Difference	Std. Mean Difference
						Total	Weight		
Study or Subgroup	Mean		Total	wean	00	Totui	weight	IV, Random, 95% CI	IV, Random, 95% CI
Study or Subgroup Brooker 2011	Mean 1.35		10tal 113	1.36	0.5714	114	26.3%	-0.02 [-0.28, 0.24]	IV, Random, 95% Cl
		SD							IV, Random, 95% Cl
Brooker 2011	1.35 0.74	SD 0.5714	113	1.36	0.5714	114	26.3%	-0.02 [-0.28, 0.24]	IV, Random, 95% Cl
Brooker 2011 Chenoweth 2009	1.35 0.74	SD 0.5714 0.74	113 77	1.36 0.68	0.5714 0.72	114 64	26.3% 23.4% 22.8%	-0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41]	IV, Random, 95% Cl
Brooker 2011 Chenoweth 2009 Chenoweth 2014	1.35 0.74 24	SD 0.5714 0.74 24.0199	113 77 64	1.36 0.68 25	0.5714 0.72 28.0233	114 64 64	26.3% 23.4% 22.8%	-0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31]	IV, Random, 95% Cl
Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013	1.35 0.74 24 1.1	SD 0.5714 0.74 24.0199 0.4	113 77 64 149 46	1.36 0.68 25 0.9	0.5714 0.72 28.0233 0.35	114 64 64 153 44	26.3% 23.4% 22.8% 27.5% 0.0%	-0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32]	IV, Random, 95% Cl
Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI)	1.35 0.74 24 1.1 1.5	SD 0.5714 0.74 24.0199 0.4 0.4	113 77 64 149 46 403	1.36 0.68 25 0.9 0.1	0.5714 0.72 28.0233 0.35 0.6	114 64 153 44 395	26.3% 23.4% 22.8% 27.5%	-0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32]	IV, Random, 95% Cl
Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013	1.35 0.74 24 1.1 1.5 = 0.07; Ch	SD 0.5714 0.74 24.0199 0.4 0.4 0.4	113 77 64 149 46 403 4, df = 3	1.36 0.68 25 0.9 0.1	0.5714 0.72 28.0233 0.35 0.6	114 64 153 44 395	26.3% 23.4% 22.8% 27.5% 0.0%	-0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32]	IV, Random, 95% Cl
Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect	1.35 0.74 24 1.1 1.5 = 0.07; Ch : Z = 1.00	SD 0.5714 0.74 24.0199 0.4 0.4 0.4 0.4 0.4 (P = 0.32)	113 77 64 149 46 403 4, df = 3	1.36 0.68 25 0.9 0.1 (P = 0.0	0.5714 0.72 28.0233 0.35 0.6 005); I ^a = 7	114 64 153 44 395	26.3% 23.4% 22.8% 27.5% 0.0%	-0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.15 [-0.15, 0.45]	-4 -2 0 2 4 Favours [Control] Favours [PCC]
Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect Quality of Life	1.35 0.74 24 1.1 1.5 = 0.07; Ch : Z = 1.00	<u>SD</u> 0.5714 0.74 24.0199 0.4 0.4 0.4 (P = 0.32) PCC	113 77 64 149 46 403 (df= 3	1.36 0.68 25 0.9 0.1 (P = 0.0	0.5714 0.72 28.0233 0.35 0.6 005); F = 7	114 64 153 44 395 7%	26.3% 23.4% 22.8% 27.5% 0.0%	-0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.15 [-0.15, 0.45] Std. Mean Difference	-4 -2 0 2 4 Favours [Control] Favours [PCC]
Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect Quality of Life Study or Subgroup	1.35 0.74 24 1.1 1.5 = 0.07; Ch : Z = 1.00 Mean	SD 0.5714 0.74 24.0199 0.4 0.4 0.4 (P = 0.32) PCC SD	113 77 64 149 46 403 9, df = 3	1.36 0.68 25 0.9 0.1 (P = 0.0 (<u>Mean</u>	0.5714 0.72 28.0233 0.35 0.6 005); I ^a = 7 Control SD	114 64 153 44 395 7%	26.3% 23.4% 22.8% 27.5% 0.0% 100.0%	-0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.15 [-0.15, 0.45] Std. Mean Difference IV, Random, 95% CI	-4 -2 0 2 4 Favours [Control] Favours [PCC]
Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect Quality of Life Study or Subgroup Brooker 2011	1.35 0.74 24 1.1 1.5 = 0.07; Ch : Z = 1.00 <u>Mean</u> 2.5	SD 0.5714 0.74 24.0199 0.4 0.4 0.4 (P = 0.32) PCC SD 5.6125	113 77 64 149 46 403 4, df = 3) Total	1.36 0.68 25 0.9 0.1 (P = 0.0 (P = 0.0 (P = 0.0) (P = 0.0) (P = 0.0)	0.5714 0.72 28.0233 0.35 0.6 005); I ^e = 7 Control SD 5.7228	114 64 153 44 395 7% <u>Total</u> 131	26.3% 23.4% 22.8% 27.5% 0.0% 100.0% <u>8</u> <u>Weight</u> 19.3%	-0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.15 [-0.15, 0.45] Std. Mean Difference IV, Random, 95% CI 0.35 [0.11, 0.60]	-4 -2 0 2 4 Favours [Control] Favours [PCC]
Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau ² - Test for overall effect Quality of Life Study or Subgroup Brooker 2011 Chenoweth 2009	1.35 0.74 24 1.1 1.5 = 0.07; Ch : Z = 1.00 <u>Mean</u> 2.5 -20.8	SD 0.5714 0.74 24.0199 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4	113 77 64 149 46 403 4, df = 3) Total 126 77	1.36 0.68 25 0.9 0.1 (P = 0.0 (<u>Mean</u> 0.5 -24.4	0.5714 0.72 28.0233 0.35 0.6 005); I ^a = 7 Control SD 5.7228 13.6	114 64 153 44 395 7% <u>Total</u> 131 64	26.3% 23.4% 22.8% 27.5% 0.0% 100.0% <u>8</u> <u>Weight</u> 19.3% 12.0%	-0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.15 [-0.15, 0.45] Std. Mean Difference IV, Random, 95% CI 0.35 [0.11, 0.60] 0.21 [-0.12, 0.54]	-4 -2 0 2 4 Favours [Control] Favours [PCC]
Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau ² - Test for overall effect Quality of Life Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014	1.35 0.74 24 1.1 1.5 = 0.07; Ch : Z = 1.00 <u>Mean</u> 2.5 -20.8 106	<u>SD</u> 0.5714 0.74 24.0199 0.4 0.4 (P = 0.32) PCC <u>SD</u> 5.6125 19.3049 12.01	113 77 64 149 46 403 46 , df = 3) Total 126 77 64	1.36 0.68 25 0.9 0.1 (P = 0.0 (P = 0.0 (P = 0.0) (P = 0.	0.5714 0.72 28.0233 0.35 0.6 005); IP = 7 005); IP = 7 5.7228 13.6 16.0133	114 64 153 44 395 7% <u>Total</u> 131 64 64	26.3% 23.4% 22.8% 27.5% 0.0% 100.0% <u>8</u> <u>Weight</u> 19.3%	-0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.15 [-0.15, 0.45] Std. Mean Difference IV, Random, 95% CI 0.35 [0.11, 0.60] 0.21 [-0.12, 0.54] 0.21 [-0.14, 0.56]	-4 -2 0 2 4 Favours [Control] Favours [PCC]
Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect Quality of Life Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Dichter 2015	1.35 0.74 24 1.1 1.5 = 0.07; Ch : Z = 1.00 <u>Mean</u> 2.5 -20.8 106 29.23	<u>SD</u> 0.5714 0.74 24.0199 0.4 0.4 (P = 0.32) PCC <u>SD</u> 5.6125 19.3049 12.01 10.9913	113 77 64 149 46 403 3, df = 3) Total 126 77 64 52	1.36 0.68 25 0.9 0.1 (P = 0.0 Mean 0.5 -24.4 103 32.58	0.5714 0.72 28.0233 0.35 0.6 005); IF = 7 005); IF = 7 5.7228 13.6 16.0133 11.1017	114 64 153 44 395 7% Total 131 64 64 53	26.3% 23.4% 22.8% 27.5% 0.0% 100.0% <u>Weight</u> 19.3% 12.0% 11.1%	-0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.15 [-0.15, 0.45] Std. Mean Difference IV, Random, 95% Cl 0.35 [0.11, 0.60] 0.21 [-0.12, 0.54] 0.21 [-0.14, 0.56] Not estimable	-4 -2 0 2 4 Favours [Control] Favours [PCC]
Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau*: Test for overall effect Quality of Life Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Dichter 2015 Goldberg 2013	1.35 0.74 24 1.1 1.5 = 0.07; Ch : Z = 1.00 <u>Mean</u> 2.5 -20.8 106 29.23 91	SD 0.5714 0.74 24.0199 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.5 0.32) PCC SD 5.6125 19.3049 12.01 10.9913 16	113 77 64 149 46 403 5, df = 3 0 Total 126 77 64 52 150	1.36 0.68 25 0.9 0.1 (P = 0.0 (P = 0.0 (P = 0.0 (<u>Mean</u> 0.5 -24.4 103 32.58 92	0.5714 0.72 28.0233 0.35 0.6 005); F = 7 005); F = 7 5.7228 13.6 16.0133 11.1017 15	114 64 153 44 395 7% Total 131 64 53 138	26.3% 23.4% 22.8% 27.5% 0.0% 100.0% 100.0% <u>Weight</u> 19.3% 12.0% 11.1% 21.2%	-0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.15 [-0.15, 0.45] Std. Mean Difference IV, Random, 95% CI 0.35 [0.11, 0.60] 0.21 [-0.14, 0.56] Not estimable -0.06 [-0.30, 0.17]	-4 -2 0 2 4 Favours [Control] Favours [PCC]
Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect Quality of Life Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Dichter 2015	1.35 0.74 24 1.1 1.5 = 0.07; Ch : Z = 1.00 <u>Mean</u> 2.5 -20.8 106 29.23	SD 0.5714 0.74 24.0199 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4	113 77 64 149 46 403 5, df = 3) Total 126 77 64 52 150 158	1.36 0.68 25 0.9 0.1 (P = 0.0 <u>Mean</u> 0.5 -24.4 103 32.58 92 -22.8	0.5714 0.72 28.0233 0.35 0.6 005); IF = 7 005); IF = 7 5.7228 13.6 16.0133 11.1017	114 64 153 44 395 7% Total 131 64 64 53	26.3% 23.4% 22.8% 27.5% 0.0% 100.0% <u>Weight</u> 19.3% 12.0% 11.1%	-0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.15 [-0.15, 0.45] Std. Mean Difference IV, Random, 95% Cl 0.35 [0.11, 0.60] 0.21 [-0.12, 0.54] 0.21 [-0.14, 0.56] Not estimable	-4 -2 0 2 4 Favours [Control] Favours [PCC]
Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau [#] = Test for overall effect Quality of Life Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Dichter 2015 Goldberg 2013 Rokstad 2013 van de Ven 2013	1.35 0.74 24 1.1 1.5 = 0.07; Ch : Z = 1.00 Mean 2.5 -20.8 106 29.23 91 -21.4	SD 0.5714 0.74 24.0199 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4	113 77 64 149 46 403 5 df = 3 0 Total 126 77 64 52 150 158 74	1.36 0.68 25 0.9 0.1 (P = 0.0 <u>Mean</u> 0.5 -24.4 103 32.58 92 -22.8	0.5714 0.72 28.0233 0.35 0.6 005); I ^a = 7 005); I ^a = 7 5.7228 13.6 16.0133 11.1017 15 7.4	114 64 64 153 44 395 7% Total 131 64 64 53 138 150 102	26.3% 23.4% 22.8% 27.5% 0.0% 100.0% 100.0% <u>Weight</u> 19.3% 12.0% 11.1% 21.2% 22.2% 14.2%	-0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.15 [-0.15, 0.45] Std. Mean Difference IV, Random, 95% CI 0.35 [0.11, 0.60] 0.21 [-0.12, 0.54] 0.21 [-0.14, 0.56] Not estimable -0.06 [-0.30, 0.17] 0.19 [-0.03, 0.42] 0.09 [-0.21, 0.39]	-4 -2 0 2 4 Favours [Control] Favours [PCC]
Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect Quality of Life Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Dichter 2015 Goldberg 2013 Rokstad 2013	1.35 0.74 24 1.1 1.5 = 0.07; Ch : Z = 1.00 Mean 2.5 -20.8 106 29.23 91 -21.4	SD 0.5714 0.74 24.0199 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4	113 77 64 149 46 403 5, df = 3) Total 126 77 64 52 150 158	1.36 0.68 25 0.9 0.1 (P = 0.0 <u>Mean</u> 0.5 -24.4 103 32.58 92 -22.8	0.5714 0.72 28.0233 0.35 0.6 005); I ^a = 7 005); I ^a = 7 5.7228 13.6 16.0133 11.1017 15 7.4	114 64 64 153 44 395 7% Total 131 64 64 53 138 150 102	26.3% 23.4% 22.8% 27.5% 0.0% 100.0% 100.0% 19.3% 12.0% 11.1% 21.2% 22.2%	-0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.15 [-0.15, 0.45] Std. Mean Difference IV, Random, 95% CI 0.35 [0.11, 0.60] 0.21 [-0.12, 0.54] 0.21 [-0.14, 0.56] Not estimable -0.06 [-0.30, 0.17] 0.19 [-0.30, 0.42]	-4 -2 0 2 4 Favours [Control] Favours [PCC]
Brooker 2011 Chenoweth 2009 Chenoweth 2014 Fossey 2006 Goldberg 2013 Total (95% CI) Heterogeneity: Tau [#] = Test for overall effect Quality of Life Study or Subgroup Brooker 2011 Chenoweth 2009 Chenoweth 2014 Dichter 2015 Goldberg 2013 Rokstad 2013 van de Ven 2013	1.35 0.74 24 1.1 1.5 = 0.07; Ch : Z = 1.00 Mean 2.5 -20.8 106 29.23 91 -21.4 -62.45 0.01; Chi ²	SD 0.5714 0.74 24.0199 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4	113 77 64 149 46 403 4, df = 3 5 7 126 77 64 52 150 158 74 449	1.36 0.68 25 0.9 0.1 (P = 0.0 (P = 0.0 (P = 0.0 (P = 0.0 (P = 0.0 (P = 0.0) (P = 0.0) (2 = 0.0)	0.5714 0.72 28.0233 0.35 0.6 005); F = 7 005); F = 7 5.7228 13.6 16.0133 11.1017 15 7.4 18.9871	114 64 64 153 44 395 7% Total 131 64 64 53 138 150 102	26.3% 23.4% 22.8% 27.5% 0.0% 100.0% 100.0% <u>Weight</u> 19.3% 12.0% 11.1% 21.2% 22.2% 14.2%	-0.02 [-0.28, 0.24] 0.08 [-0.25, 0.41] -0.04 [-0.38, 0.31] 0.53 [0.30, 0.76] 2.73 [2.15, 3.32] 0.15 [-0.15, 0.45] Std. Mean Difference IV, Random, 95% CI 0.35 [0.11, 0.60] 0.21 [-0.12, 0.54] 0.21 [-0.14, 0.56] Not estimable -0.06 [-0.30, 0.17] 0.19 [-0.03, 0.42] 0.09 [-0.21, 0.39]	-4 -2 0 2 4 Favours [Control] Favours [PCC]

https://doi.org/10.1371/journal.pone.0212686.g003

between the person-centered care group and the control group; SMD -0.05 (95% CI -0.17 to 0.07; studies 5; participants = 1043; $I^2 = 0$ %).

Depression. Six studies [34,36,44,46,47,49] produced no difference in the standardized mean depression score (SMD 0.00, 95% CI -0.21 to 0.21; studies = 6; I² = 59%). Sensitivity analysis of four studies with low risk of bias [34, 36,44,47] similarly showed no significant differences in mean depression scores for person-centred care or usual care (p = 0.87, SMD 0.01 and 95% CI -0.13 to 0.16). Five of the studies with low heterogeneity [34,44,46,47,49] showed no change in depression with person-centered care or usual care (SMD -0.06 and 95% CI-0.27 to 0.15, studies = 5; participants = 861; I² = 53%).

Well-being. Six studies [15,33,43,38,45,49] showed a non-significant increase in the standardized mean well-being score in person-centered care compared to usual care (SMD 0.64, 95% CI -0.37 to 1.65; studies = 6; I² = 98%). After excluding two studies with high risk of bias [38,45] the overall mean score in the person-centered care group remained significantly higher than in the usual care group (p = 0.002, SMD 0.25, 95% CI 0.09 to 0.40). Four of the studies with low heterogeneity [15,33,34,49] however, produced a non-significant improvement in well-being with person-centered care (SMD 0.15, 95% CI -0.15 to 0.45; studies = 4; participants = 798; I² = 77%).

Quality of life. Seven studies [33,34,37,38,47,48,49] produced a non-significant improvement in standardized mean quality of life scores with person-centered care, compared with usual care (SMD 0.11 and 95% CI -0.04 to 0.26; studies = 7; I² = 47%). Analysis of three studies with low risk of bias (33,34,47] showed a significant effect in the quality of life score in the person-centered care group (p = 0.02, SMD 0.2, 95% CI 0.04 to 0.36). Six of the studies with low heterogeneity [33,34,38,47,48,49] showed a significant improvement in quality of life with person-centered care (SMD 0.16 and 95% CI 0.03 to 0.29; studies = 6; participants = 1298; I² = 29%).

Secondary participant outcomes

Data for secondary outcomes, function in activities of living, physical and chemical restraint and adverse events, were neither sufficient nor sufficiently similar to undertake an analysis. Nevertheless, a review of the reported results of individual trials indicated a mixed trend towards improvement in some activities of living, mainly physical function [33,36,44,45,46]and engagement in leisure/social activities [33,34,45,49] (studies = 7; participants = 1298; p = 0.01 to 0.58), and also a trend towards a reduction in the use of physical restraint [33,34](studies = 2; participants = 890; p = 0.02 to 0.006). There was variable success in reducing use of chemical restraint with person-centered care [33,48] (studies = 2; participants = 915; p = 0.08 to 0.66), and in preventing adverse events such as falls [33,34,36,48] (studies = 4; participants = 1109; p = 0.03 to 0.27).

Discussion

The review identified 12 studies that met the inclusion criteria for assessing the effectiveness of PCC delivered at the organizational level for people living with dementia as recommended in the VIPS guidelines [23] and the PCECAT instrument [26]. While the results showed a significant effect for increased quality of life, and a non-significant improvement in neuropsychiatric symptoms and well-being, there was no evidence that demonstrated a reduction in agitation and depression. Apart from demonstrating no effect for agitation, these findings concur with the results of three systematic reviews of PCC for people living with dementia [14,50,51]. Similar with previous findings [51,52], delivery of PCC at the organizational level did not have a positive impact on level or rates of depression in people living with dementia.

In all likelihood, the mixed trial results for reducing agitation specifically, one of the most common types of neuropsychiatric symptoms experienced by people with dementia, may reflect the intention of most studies to obtain these data in relation to the person's behaviour in general, rather than in relation to specific care events, such as during personal care when an agitation response is more likely to occur. Another possible reason for the mixed results for agitation is the complexity of an organizational-wide implementation of the PCC approach. Implementation of PCC is dependent upon a number of factors that are not always measured in PCC trials, for example, organizational culture, staffing levels, staff skill-sets and mix, and the physical and psycho-social care environment.

There can be limited confidence in the findings of this review, given the moderate to high methodological quality of the 12 included studies in relation to the clear reporting of the study designs and methods. A majority of the studies had low risk of bias overall, with the exception of performance bias common in CRCTs and quasi-experimental studies. All 12 studies included participants of similar ages and clinical characteristics, including a valid diagnosis of dementia, and exhibiting neuropsychiatric symptoms which caregiving staff found trouble-some. As expected in this vulnerable population, there was a 25–30% participant loss-to-follow-up in studies conducted in the long-term care setting, mainly due to the death of participants. The variation in time to follow-up in the different studies, ranging from 6–18 months in the long-term care setting and two to 3 weeks in the hospital setting, is explained by the focus of these different settings and thus, the longer predicted length of stay in the long-term care setting compared with the hospital setting. Being able to achieve improved quality of life in people with advanced dementia through the delivery of PCC in both of these settings has important clinical and policy implications.

Another cause for confidence in the review findings is that all 12 studies obtained baseline and follow-up outcome data using validated measures for the primary outcomes and for most of the secondary outcomes. Many of the studies employed the same validated outcome measures (refer Table 1), which enabled robust statistical analyses of the combined results.

While all studies showed improvements in at least one primary outcome using multi-modal implementation of PCC as outlined in the VIPS guidelines [24], the implementation procedures were not standardized across studies. All of the studies did adhere, however, to the principle of aiming to support personhood through the provision of individualized care, therapy and activity programs by all direct caregivers and therapy staff, as well as adhering to the principle of requiring all staff to interpersonally communicate and engage with the person in ways that encouraged their self-determination, self-respect, dignity and well-being.

Another common feature of all studies was the operation of PCC at the organizationallevel, as recommended in the VIPS framework [24]. Organisational-level interventions included a combination of: staff education, training, guidance and exposure to role modelling in how to understand and interpret verbal and non-verbal communication from the perspective of the person with dementia; and providing the person with interesting, purposeful, and meaningful things to do in their daily life, in consultation with the person, their family and caregivers. Person-centered care and leisure/social activities all included approaches that were meaningful for the person, such as communicating with them about their memories of family, friends, places and events. When the whole care team employed this approach, it was found to increase the person's participation in care and leisure/social activities, which in most studies also improved psychosocial and functional outcomes, albeit non-significantly.

These outcomes support Kitwood's [7] theoretical assumption that positive interpersonal relationships and enriched care environments can prevent the disabling effects of dementia and promote a sense of well-being for the person [6,8,9]. A recent study evaluating an organisation-wide PCC model in Norwegian aged care homes found a positive relationship between

a person-centered organisation, care staff work practices and organizational systems established to support the model [52].

Limitations

A limitation of the review was the difference in measurement points across studies, varying from three weeks in the hospital setting at follow-up to 18 months follow-up in the long-term care and community-based settings. Variance in data collection points occurred because of the different functions of the study settings and the aims of the different PCC intervention programs, as well as the differences in anticipated participant lengths-of-stay in these very different care settings. The decision was, therefore, made to undertake an analysis of all primary outcomes with data obtained within 12-months after baseline. This limitation needs to be considered when analysing the effects of PCC in studies within different contexts and follow-up periods.

As identified, depending on the study context and anticipated participant loss to follow-up of between 25–35%, the included studies had variable duration of the PCC intervention as follows: 3–4 weeks [36,45]; 3 months [44], 7–8 months [33,34,38,48], 10–12 months [15,46,47], and 18 months [37,49]. However, other than in the two studies that had very short follow-up assessment periods [36,45] where there was no or minimal participant dropout, the differences in the duration of PCC in the remaining 10 studies did not appear to have a measurable effect on the primary outcomes assessed.

Another limitation of the analyses is that while 10 of the12 included studies used more than one measure to assess some of the primary and secondary outcomes, the results of only one of the most frequently used primary outcome measures were analysed, e.g. pooled agitation results were analysed for the seven studies which reported the Cohen-Mansfield Agitation Inventory scores [53] (Refer to Table 1 for all outcome measures). The results may have changed if the primary outcome results had included the pooled data of all the different outcome measures used to assess the same constructs, e.g. where more than one outcome measure was used in any one study to assess quality of life.

A possible limitation of the review was the inclusion of studies with moderate to high risk of bias [37,46, 49]. These studies had a high risk of bias in three or more areas, including for neuropsychiatric symptoms [37,46], agitation [46], depression [47,49] and quality of life [37]. Although these studies' results were included in the initial analysis (Fig 2), they were excluded when undertaking additional analyses of low bias studies, which produced more favourable results in the person-centred care group for agitation, well-being and quality of life.

Analysis of secondary outcomes was not possible because there were insufficient data using comparable instruments. In the case of activities of living, for example, it was not possible to pool the data in studies using the DCM [54] activities of living codes and data obtained with other validated measures. As well, there was statistical heterogeneity of study results and an insufficient number of studies to undertake analyses of secondary outcomes.

Implications for research

This review has highlighted a number of issues which should be considered when designing future research on the organization-wide implementation of PCC. It would be useful to standardize methods of education, training and supervision of PCC and person-centred recreation, social and therapy programs, in order to compare outcomes for different study populations and across various care settings, and in people with mild, moderate and severe dementia. Minimally, the specific approaches to PCC education, training and supervision that have been employed should be reported, thus enabling comparison across studies. As

well, it will be important to determine the required minimum number of hours of personcentred education, training and supervision required, the optimal dose and duration of PCC support required, and the dose of the individual components of PCC operating at the organisational level that is required, to produce positive outcomes for the person living with dementia.

As different contexts of care (acute, supported care housing, long-term care) will determine the potential dose and duration of PCC interventions, it will be important to distinguish the immediate and longer-term outcomes for people living with dementia in these different care situations (or contexts). Further research is needed to evaluate PCC outcomes at critical points in the person's care trajectory, such as when a significant change in health status occurs. Additionally, further assessment of the delivery of PCC in different locations (hospital and community-based settings) and assessment of care provision by different types of staff, carers and family, would provide valuable information to understand how organizations can best support and deliver the PCC model across the whole organization. This is particularly important when considering how best to provide supportive services and care for people with terminal dementia in ways that are supportive of their end-of-life needs.

Since there is considerable overlap between neurological symptoms, mood and quality of life in people with dementia, and multiple factors involved in their expression, it is important when assessing these outcomes to consider the inter-relationships between the person, their caregivers and features of the care environment. It may be useful, therefore, to measure a number of dimensions associated with the outcomes of interest including physiological, psychological, spiritual, social, and personal preferences, and to recognize that various dimensions may hold different salience for individuals living with dementia. Consequently, novel and innovative approaches are required to evaluate the benefits of particular organizational systems and care practices for the individual. None of the included studies undertook a comprehensive cost-effectiveness analysis of the models of PCC implemented, therefore, future research is urgently required to assess the efficiencies as well as the effectiveness of quality aged care systems.

Conclusions

This systematic review of organizational-level implementation of PCC suggests that where PCC operates at the organizational level, with the full support of organizational leaders, it can increase quality of life in people living with dementia, and it can potentially improve their well-being and reduce neuropsychiatric symptoms. While dementia is a progressive, incurable illness, improving the quality of life for people who experience it is of clinical significance. Maintaining dignity and personhood in the face of this illness is consistent with the humanistic values underpinning quality health care.

Supporting information

S1 Table. Included studies measurement references. (DOCX)
S2 Table. PRISMA checklist plos 1. (DOC)
S1 Fig. MEDLINE search strategy. (DOCX)

Acknowledgments

The authors acknowledge the contribution by invited reviewer EB, who evaluated and consulted with SL and AYW about the two published CRCTs of which LC and JSP were chief investigators and thank her sincerely for assisting with this aspect of the review. Also acknowledged are members of the Cochrane Dementia and Cognitive Improvement Group who accessed potentially suitable article abstracts for the authors.

Author Contributions

Conceptualization: Lynette Chenoweth.

Data curation: Lynette Chenoweth, Jane Stein-Parbury, Samuel Lapkin.

Formal analysis: Lynette Chenoweth, Jane Stein-Parbury, Samuel Lapkin, Alex Wang, Zhixin Liu.

Investigation: Lynette Chenoweth, Jane Stein-Parbury, Samuel Lapkin.

Methodology: Lynette Chenoweth, Jane Stein-Parbury, Samuel Lapkin, Alex Wang, Zhixin Liu.

Project administration: Lynette Chenoweth.

Supervision: Alex Wang.

Validation: Jane Stein-Parbury, Samuel Lapkin, Alex Wang, Zhixin Liu, Anna Williams.

Writing – original draft: Lynette Chenoweth, Jane Stein-Parbury, Samuel Lapkin, Alex Wang.

Writing – review & editing: Lynette Chenoweth, Jane Stein-Parbury, Samuel Lapkin, Alex Wang, Zhixin Liu, Anna Williams.

References

- 1. World Health Organization (WHO). Towards a dementia plan: a WHO guide. Geneva; 2018. Licence: CC BY-NC-SA 3.0 IGO.
- 2. Alzheimer's Association. Alzheimer's Facts and Figures 2013. Available at: http://www. dementiajourneys.com/wp/2013/05/04/alzheimers-disease-facts/
- 3. Alzheimer's Disease International, Alzheimer's Australia. Dementia in the Asia Pacific Region. London: Alzheimer's Disease International; 2014.
- 4. McCormack B, McCance T. Person-centred nursing: theory and practice. Chichester: John Wiley & Sons; 2011.
- Kitson A, Marshall A, Bassett K, Zeitz K. What are the core elements of patient-centred care? A narrative review and synthesis of the literature from health policy, medicine and nursing. J Adv Nurs. 2013; 69(1): 4–15. https://doi.org/10.1111/j.1365-2648.2012.06064.x PMID: 22709336
- Morgan S, Yoder LH. A concept analysis of person-centered care. J Holist Nurs. 2012; 30(1): 6–15. https://doi.org/10.1177/0898010111412189 PMID: 21772048
- 7. Kitwood TM. Dementia reconsidered: the person comes first. Buckingham: Open University Press; 2007.
- 8. Brooker D. What is person-centred care in dementia? Rev Clin Gerontol. 2004; 13: 215–22.
- Dewing J. Personhood and dementia: revisiting Tom Kitwood's ideas. Int J Older People Nurs. 2008; 3: 3–13. https://doi.org/10.1111/j.1748-3743.2007.00103.x PMID: 20925884
- National Voices. Person-centered care in 2017. Evidence from service users. Available from: https://www.nationalvoices.org.uk/sites/default/files/public/publications/person-centred_care_in_2017_-national_voices.pdf. 2017
- 11. Berry L. The National Dementia Strategy: transforming care. Nurs Older People. 2009; 21(1): 3. PMID: 19248432

- Australian Health Ministers Advisory Council (AHMAC). National Framework for Action on Dementia 2015–2019. Canberra, Australia: AHMAC; 2015.
- Sloane PD, Hoeffer B, Mitchell CM, McKenzie DA, Barrick AL, Rader J, et al. Effect of person-centered showering and the towel bath on bathing associated aggression, agitation, and discomfort in nursing home residents with dementia: A randomized, controlled trial. J Am Geriatr Soc. 2004; 52: 1795–804. https://doi.org/10.1111/j.1532-5415.2004.52501.x PMID: 15507054
- Brownie S, Nancarrow S. Effects of person-centered care on residents and staff in aged-care facilities: a systematic review. Clin Interv Aging. 2013; 8: 1–10. https://doi.org/10.2147/CIA.S38589 PMID: 23319855
- Fossey J, Ballard C, Juszczak E, James I, Alder N, Jacoby R, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ 2006; 332: 756–761. https://doi.org/10.1136/bmj.38782.575868.7C PMID: 16543297
- Moore L, Britten N, Lydahl D, Naldemirci Ö, Elam M, Wolf A. Barriers and facilitators to the implementation of person-centred care in different healthcare contexts. Scand J Caring Sci. 2017; 31: 662–673. https://doi.org/10.1111/scs.12376 PMID: 27859459
- Doyle PJ, Rubinstein RL. Person-centered dementia care and the cultural matrix of othering. Gerontologist. 2013; 54(6): 952–963. https://doi.org/10.1093/geront/gnt081 PMID: 23921807
- Eriksen S, Helvik A-S, Juvet LK, Skovdahl K, Forsund LH, Grov EK. The experience of relations in persons with dementia: a systematic meta-synthesis. Dement Geriatr Cogn Disord. 2016; 42: 342–368. https://doi.org/10.1159/000452404 PMID: 27866199
- Chenoweth L, Jeon YH, Stein-Parbury J, Forbes I, Fleming R, Cook J, Cheah S, Fletcher S, Tinslay L. PerCEN trial participant perspectives on the implementation and outcomes of person-centered dementia care and environments. Int Psychogeriatr. 2015; 27(12): 2045–2057. https://doi.org/10.1017/ S1041610215001350 PMID: 26307245
- Røsvik J, Brooker D, Mjorud M, Kirkevold Ø. What is person-centred care in dementia? Clinical reviews into practice: the development of the VIPS practice model. Rev Clin Gerontol. 2013; 23(2): 155–163.
- Jeon YH, Simpson JM, Li Z, Cunich MM, Thomas TH, Chenoweth L, Kendig HL. Cluster randomized controlled trial of an aged care specific leadership and management program to improve work environment, staff turnover, and care quality. J Am Med Dir Assoc. 2015; 16(17): 629.e19–629.e28.
- 22. Love K, Pinkowitz J. Person-centered care for people with dementia: A theoretical and conceptual framework. Gener. 2013; 37(3): 23–29.
- Slater L. Person-centredness: A concept analysis. Contemp Nurse.2006; 23: 135–144. <u>https://doi.org/10.5555/conu.2006.23.1.135 PMID: 17083326</u>
- Brooker D. Person-centred dementia care: Making services better. London: Jessica Kingsley Publishers; 2007.
- Bradford Dementia Group and the Commission for Social Care Inspection in England. Short Observational Framework for Inspection (SOFI 2). Bradford, UK: University of Bradford; 2007.
- Burke C, Stein-Parbury J, Luscombe G. Chenoweth L. 2016. Development and testing of the Person-Centred Environment and Care Assessment Tool (PCECAT). Clinical Gerontologist, 2016; 39(4):282– 308.
- Chenoweth L, Stein Parbury J, Lapkin S, Wang YA. Organisational interventions for promoting person centred care for people with dementia. Cochrane Database Syst Rev. 2015, Issue 11. Art. No.: CD011963. https://doi.org/10.1002/14651858.CD011963
- American Psychiatric Association. Diagnostic and Statistical Manual (DSM-5). 5th edition. Washington DC: American Psychiatric Association; 2013.
- 29. World Health Organisation (WHO). International Statistical Classification of Diseases and Related Health Problems. Geneva: World Health Organization; 2015.
- ALOIS, The Cochrane Dementia and Cognitive Improvement Group Specialised Register, 2011. Available from: http://www.medicine.ox.ac.uk/alois
- **31.** Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. New Jersey: Wylie and Sons; 2011.
- **32.** Ryan R, Hill S. How to GRADE the quality of the evidence. Cochrane Consumers and Communication Group, available at http://cccrg.cochrane.org/author-resources. Version 3.0 December 2016.
- 33. Chenoweth L, King MT, Jeon Y-H, Brodaty H, Stein-Parbury J, Norman R, et al. Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial. Lancet Neurol. 2009; 8: 317–325. https://doi.org/10.1016/ S1474-4422(09)70045-6 PMID: 19282246

- Chenoweth L., Forbes I., Fleming R., King M., Stein-Parbury J., Luscombe, et al. PerCEN: a cluster randomised controlled trial of person-centred environment outcomes for people with dementia. Int Psychogeriatr. 2014; 26(7): 1147–1160. https://doi.org/10.1017/S1041610214000398 PMID: 24666667
- Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ (Online). 2014; 348: g1687
- Cohen-Mansfield J, Thein K, Marx MS, Dakheel-Ali M, Freedman L. Efficacy of nonpharmacologic interventions for agitation in advanced dementia: a randomized, placebo-controlled trial. J Clin Psychiatry. 2012; 73(9): 478–1261.
- Dichter MN, Quasdorf T, Schwab CG, Trutschel D, Haastert B, Riesner C, et al. Dementia care mapping: effects on residents' quality of life and challenging behavior in German nursing homes. A quasiexperimental trial. Int Psychogeriatr. 2015; 27(11):1875–1892. <u>https://doi.org/10.1017/S1041610215000927 PMID: 26138674</u>
- Goldberg SE, Bradshaw LE, Kearney FC, Russell C, Whittamore KH, Foster PE, et al. Care in specialist medical and mental health unit compared with standard care for older people with cognitive impairment admitted to general hospital: randomised controlled trial (NIHR TEAM trial). BMJ (Online). 2013; 347: f4132.
- Review Manager (RevMan). Version 5.3 [Computer program]. The Nordic Cochrane Centre, The Cochrane Collaboration. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
- 40. R Foundation for Statistical Computing, Vienna, Austria.
- Effective Practice and Organisation of Care (EPOC). EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services; 2015. Available at: https://epoc.cochrane.org/ resources/epoc-resources-review-authors
- Peters JL, Mengersen KL. Meta-analysis of repeated measures study designs. J Eval Clin Pract. 2008; 14(5): 941–950. https://doi.org/10.1111/j.1365-2753.2008.01010.x PMID: 19018929
- 43. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med, 2009; 6(7): e1000097. https://doi.org/10.1371/journal.pmed.1000097 PMID: 19621072
- 44. Finnema 2005; Finnema E, Dröes RM, Ettema T, Ooms M, Adèr H, Ribbe M, et al. The effect of integrated emotion-oriented care versus usual care on elderly persons with dementia in the nursing home and on nursing assistants: a randomized clinical trial. Int J Geriatr Psychiatry. 2005; 20(4): 330–343. https://doi.org/10.1002/gps.1286 PMID: 15799079
- 45. Li J, Grandner MA, Chang YP, Jungquist C, Porock D. Person-centered dementia care and sleep in assisted living residents with dementia: a pilot study. Behav Sleep Med. 2017; 15(2): 97–113. <u>https:// doi.org/10.1080/15402002.2015.1104686</u> PMID: 26681411
- Lawton MP, Van Haitsma K, Klapper J, Kleban MH, Katz IR, Corn J. A stimulation-retreat special care unit for elders with dementing illness. Int Psychogeriatr. 1988; 10(4): 379–395.
- Rokstad AM, Røsvik J, Kirkevold Ø, Selbaek G, Benth JS, Engedal K. The effect of person-centred dementia care to prevent agitation and other neuropsychiatric symptoms and enhance quality of life in nursing home patients: a 10-month randomized controlled trial. Dement Geriatr Cogn Disord. 2013; 36 (5–6): 340–353. https://doi.org/10.1159/000354366 PMID: 24022375
- 48. van de Ven G, Draskovic I, Adang EM, Donders R, Zuidema SU, Koopmans RT, et al. Effects of dementia-care mapping on residents and staff of care homes: a pragmatic cluster-randomised controlled trial. PloS One. 2013;. 8(7): e67325. https://doi.org/10.1371/journal.pone.0067325 PMID: 23844003
- Brooker DJ, Argyle E, Scally AJ, Clancy D. The enriched opportunities programme for people with dementia: a cluster-randomised controlled trial in 10 extra care housing schemes. Aging Ment Health. 2011; 15(8): 1008–1017. https://doi.org/10.1080/13607863.2011.583628 PMID: 21702705
- Kogan AC, Wilber K, Mosqueda L. Person Centered Care for Older Adults with Chronic Conditions and Functional Impairment: A Systematic Literature Review. J Am Geriatr Soc 2016; 64(1): 1–7.
- Olsson LE, Jakobsson Ung E, Swedberg K, Ekman I. Efficacy of person centred care as an intervention in controlled trials: a systematic review. J Clin Nurs. 2013; 22(3–4): 456–465. <u>https://doi.org/10.1111/jocn.12039 PMID: 23231540</u>
- Røen I, Kirkevold Ø, Testad I, Selbæk G, Engedal K, Bergh S. Person-centered care in Norwegian nursing homes and its relation to organizational factors and staff characteristics: a cross-sectional survey. Int Psychogeriatr. 2018; 30(9): 1279–1290. https://doi.org/10.1017/S1041610217002708 PMID: 29198221
- Cohen-Mansfield J. Measurement of inappropriate behaviour associated with dementia. J Gerontol Nurs. 1999; 25: 42–51.
- 54. Bradford Dementia Group. DCM 8 user's manual. Bradford: University of Bradford; 2005.